Originally published in Pharma’s Almanac The healthcare burden of cancer is increasing worldwide. There were an estimated 18 million new cancer cases in 2018,1 a 28% annual increase from 2012. Alarmingly, by 2030, annual diagnoses are expected to increase another 31%
Is the U.S. Biosimilars Market Poised for Takeoff?
4 Questions on Our Minds as We Head to Chemspec Europe 2019
Leaders of Transformation

Haig Armaghanian Leads the Conversation with Synthetic Biology Executives Revolutionizing Therapeutic Development The therapeutic breakthroughs that are hitting the pages of scientific publications and news media outlets almost every day can make it feel as though this revolutionary medical progress
Service Shifts in the Automotive Industry Are Driving Profound Change. Are You Ready?
The Evolution of API Route Decisions

How advancements in biocatalytic capabilities have added to the API development and manufacturing toolbox Until recently, pharmaceutical active product ingredient (API) developers were limited to selecting from a roster of chemical catalysts to perform the transformations needed for drug manufacturing.
Increasing the Speed of the Synthetic Biology Design-Build-Test-Learn Pipeline
The synthetic biology field has the power to revolutionize many industries including chemicals, food, material science, molecular biology, pharmaceuticals, biotherapeutics, and many others. Synthetic biology has come a long way, and the very cost-effective ability to read and write DNA
Emily Leproust Discusses Synthetic Biology’s Role in Transforming Therapeutics
The rapidly developing field of synthetic biology has the power to revolutionize many industries including chemicals, food, material science, molecular biology, pharmaceuticals, biotherapeutics, and many others. While numerous fields will and are benefiting from synthetic biology advancements, the medical and
2019 Has Arrived. So, What’s Ahead for the Biopharmaceutical Industry?
by Haig Armaghanian As the new year begins, it’s helpful to look back at 2018 for clues as to what might be ahead. 2018 was a good year for biopharma. Profits were strong, IPO activity was robust, and Takeda’s $62